التداخل بين ليناليدوميد وريتوكسيماب

In the AUGMENT and MAGNIFY trials, Grade 3 or 4 neutropenia was reported in 50% and 33%, respectively, of patients in the REVLIMID/rituximab arm.

Grade 3 or 4 thrombocytopenia was reported in 2% and 8%, respectively, of patients in the REVLIMID/rituximab arm [see Adverse Reactions (6.1) ] .

In the AUGMENT trial, the incidence of VTE (including DVT and PE) in FL or MZL patients was 3.4% in the REVLIMID/rituximab arm [see Adverse Reactions (6.1) ] .

In the AUGMENT trial, the incidence of ATE (including MI) in FL or MZL patients was 0.6% in the REVLIMID/rituximab arm [see Adverse Reactions (6.1) ] .

In the AUGMENT trial with FL or MZL patients receiving REVLIMID/rituximab therapy, hematologic plus solid tumor SPMs, notably AML, have been observed.